Medical/Pharmaceuticals

Meihua International Medical Technologies Co., Ltd. Announces Closing of $39.4 Million Initial Public Offering

YANGZHOU, China, Feb. 18, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced the closing of...

2022-02-19 05:30 7163

OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002

SEOUL, South Korea, Feb. 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain. The Phase 2a study was appr...

2022-02-18 23:00 3777

Keymed Bio Joins Hang Seng Family of Indexes

HONG KONG, Feb. 18, 2022 /PRNewswire/ --  According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...

2022-02-18 22:10 7160

TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China

NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor,...

2022-02-18 22:00 4522

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...

2022-02-18 08:19 2321

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today...

2022-02-17 21:30 3223

Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia

TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...

2022-02-17 21:00 2108

Seegene Announces Q4 and Full-Year 2021 Financial Results

* Total sales of 2021 stood at KRW 1.37 trillion, a 22% increase YoY * Q4 Revenue of KRW 410 billion, up 34% QoQ * Operating profit held steady YoY at KRW 666.7 billion despite its tripled strategic investments in R&D * Seegene to make a strategic shift to a 'molecular diagnostics(MDx) plat...

2022-02-17 20:00 3105

Small Molecule Targeting CD47-SIRPα Pathway: Insilico Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

SHANGHAI and NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, today announced that it has used its proprietary AI platform to nominate a preclinical candidate compound (PCC) for innova...

2022-02-17 16:30 3841

Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders

Resolv ER™ may remedy leading causes of blindness in adults LAGUNA HILLS, Calif., Feb. 17, 2022 /PRNewswire/ -- Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company's investigational new drug (IND) application to c...

2022-02-17 12:14 3490

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the Taiwan Food and Drug A...

2022-02-17 09:19 5503

Cambridge Nutranostics has developed a point-of-care OCCL test prototype for testing blood plasma oxygen to monitor pregnancy health

CAMBRIDGE, England, Feb. 17, 2022 /PRNewswire/ -- Cambridge Nutranostics Ltd (CNL,http://www.occltest.com ) has begun to validate in clinic its first prototype of a test to assess and monitor plasma oxygen, the part of the total blood O2, which can cross the capillary wa...

2022-02-17 09:00 2596

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dise...

2022-02-17 08:00 5669

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protei...

2022-02-16 21:00 6253

LIMACORPORATE'S ADVANCED TESTING FACILITY RECEIVES ISO 17025 CERTIFICATION BY ACCREDIA

UDINE, Italy, Feb. 16, 2022 /PRNewswire/ -- LimaCorporate is proud to announce the ISO 17025 accreditation by Accredia. This important achievement covers the activities of ATLAs, the company's Advanced Laboratory for Testing and Analysis. ATLAs is the core of the experimental verification and sim...

2022-02-16 21:00 3925

Meihua International Medical Technologies Co., Ltd. Announces Pricing of $36,000,000 Initial Public Offering

YANGZHOU, China, Feb. 16, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced the pricing of...

2022-02-16 20:34 4731

PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs

NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory A...

2022-02-16 20:00 2263

JIXING ANNOUNCES RECEIPT OF BREAKTHROUGH THERAPY DESIGNATION FOR AFICAMTEN IN CHINA

SHANGHAI, Feb. 16, 2022 /PRNewswire/ -- Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that the Center for Drug Evaluation ...

2022-02-16 18:06 4341

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Adminis...

2022-02-16 17:04 4651

Nippon Express (China) Donates Protective Suits to China Railway Express Terminal Station in Xi'an

TOKYO, Feb. 16, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NX China"), a Nippon Express Holdings, Inc. Group company, has donated protective suits to the Xi'an International Inland Port Investment & Development Group (hereinafter "ITL Group") operating the rail terminal i...

2022-02-16 15:00 3602
1 ... 589590591592593594595 ... 643